Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United StatesRevised November 3, 2000

REFERENCES

• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–1180.
   PubMed Web of Science ®Google Scholar
• CDC. Recommendations of the Public Health Service Task Force on use of zidovudine to reduce perinatal trans-mission of human immunodeficiency virus. MMWR. 1994;43(No. RR-11):1–21.
   Google Scholar
• CDC. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR. 1995;44 (No. RR-7):1–14.
   PubMedGoogle Scholar
• Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis. 1996;174:1207–1211.
   PubMed Web of Science ®Google Scholar
• Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA. 1996;275:1483–1488.
   PubMed Web of Science ®Google Scholar
• Fiscus SA, Adimora AA, Schoenbach VJ, et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis. 1999;180:99–105.
   PubMed Web of Science ®Google Scholar
• Thomas P, Singh T, Bornschlegel K, et al. Use of ZDV to prevent perinatal HIV in New York City (NYC). Proceed-ings from the Fourth Conference on Retroviruses and Opportunistic Infections; January 22–26, 1997; Washing-ton, DC. Abstract 176.
   Google Scholar
• Mayaux M-J, Teglas J-P, Mandelbrot L, et al. Acceptabil-ity and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr. 1997;131:857–862.
   PubMed Web of Science ®Google Scholar
• Simonds RJ, Steketee R, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal trans-mission of HIV. AIDS. 1998;12:301–308.
   PubMed Web of Science ®Google Scholar
• Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life span, and viral generation time. Science. 1996;271:1582–1586.
   PubMed Web of Science ®Google Scholar
• Haylir DV, Richman DD. Viral dynamics of HIV: Implica-tions for drug development and therapeutic strategies. Ann Intern Med. 1996;124:984–994.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–733.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–739.
   PubMed Web of Science ®Google Scholar
• CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR. 1998;47(RR-5):39-82 ( and updates http://www.hivatis.org).
   Google Scholar
• Mofenson LM. Interaction between timing of perinatal hu-man immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr SuppL 1997;491:1–9.
   Google Scholar
• Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): Tumori-genicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst. 1997;89:1602–1608.
   PubMed Web of Science ®Google Scholar
• Minkoff H, Augenbraun M. Antiretroviral therapy for preg-nant women. Am J Obstet GynecoL 1997;176:478–489.
   PubMed Web of Science ®Google Scholar
• Mills JL. Protecting the embryo from X-rated drugs. N Engl J Med. 1995;333:124–125.
   PubMed Web of Science ®Google Scholar
• CDC. Pregnancy outcomes following systemic prenatal acyclovir exposure- June 1, 1984 to June 30, 1993. MMWR. 1993;42:806–809.
   PubMedGoogle Scholar
• Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal ef-fects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS. 1998;12:F241- F247.
   Google Scholar
• Martin R, Boyer P, Hammill H, et al. Incidence of prema-ture birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Car-diovascular Complications of Vertically Transmitted Hu-man Immunodeficiency Virus Infection Study Group. J Pediatr. 1997;131:851–856.
   PubMed Web of Science ®Google Scholar
• Leroy V, Ladner J, Nyiraziraje M, et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. Pregnancy and HIV Study Group. AIDS. 1998;12:643–650.
   PubMed Web of Science ®Google Scholar
• Brocklehurst P, French R. The association between ma-ternal HIV infection and perinatal outcome: A systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998;105:836–848.
   PubMedGoogle Scholar
• Food and Drug Administration. FDA Public Health Advi-sory: Reports of Diabetes and Hyperglycemia in Patients Receiving Protease Inhibitors for Treatment of Human Im-munodeficiency Virus (HIV). Rockville, MD: Food and Drug Administration, Public Health Service, Department of Health and Human Services; June 11, 1997.
   Google Scholar
• Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy [letter]. Ann Intern Med. 1997;127:947.
   PubMed Web of Science ®Google Scholar
• Eastone JA, Decker CF. New-onset diabetes mellitus as-sociated with use of protease inhibitor [letter]. Ann Intern Med. 1997;127:948.
   PubMed Web of Science ®Google Scholar
• Dube M. Metabolic complications of antiretroviral thera-pies. AIDS Clin Care. 1998; 10:41–48.
   PubMedGoogle Scholar
• Brinkman K, Ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS. 1998;12:1735–1744.
   PubMed Web of Science ®Google Scholar
• Martin JL, Brown DE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38:2743–2749.
   PubMed Web of Science ®Google Scholar
• Blanche S, Tardieu M, Rustin P, et al. Persistent mito-chondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084–1089.
   PubMed Web of Science ®Google Scholar
• Smith ME, and the US Nucleoside Safety Review Working Group. Ongoing nucleoside safety review of HIV-exposed children in U.S. studies. Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants; September 1–6, 1999; Montreal, Canada. Abstract 096.
   Google Scholar
• Lange J, Stellato R, Brinkman K, et al. Review of neuro-logical adverse events in relation to mitochondrial dys-function in the prevention of mother to child transmission of HIV: PETRA study. Second Conference on Global Strat-egies for the Prevention of HIV Transmission from Mothers to Infants; September 1–6, 1999; Montreal, Canada. Ab-stract 250.
   Google Scholar
• Morris AAM, Carr A. HIV nucleoside analogues: New ad-verse effects on mitochondria? Lancet. 1999;354:1046–1047.
   Google Scholar
• Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335:1621–1629.
   PubMed Web of Science ®Google Scholar
• Sandberg JA, Slikker W Jr. Developmental pharmacology and toxicology of anti-HIV therapeutic agents: Dideoxynucleosides. FASEB J. 1995;9:1157–1163.
   PubMed Web of Science ®Google Scholar
• Qian M, Bui T, Ho RJY, Unadkat JD. Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental tro-phoblasts and hofbauer cells. Biochem Pharmacol. 1994;48:383–389.
   PubMed Web of Science ®Google Scholar
• Dancis J, Lee JD, Mendoza S, Liebes L. Transfer and metabolism of dideoxyinosine by the perfused human placenta. J Acquir Immune Defic Syndr Hum Retrovirol. 1993;6:2–6.
   Google Scholar
• Sandberg JA, Binienda Z, Lipe G, Slikker W Jr. Placental transfer and fetal disposition of dideoxycytidine (ddC) and dideoxyinosine (ddl) [Abstract]. Toxicologist 1994;14:434.
   Google Scholar
• Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent fail-ure of zidovudine therapy to prevent perinatal transmis-sion of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trial Group Protocol 076. J Infect Dis. 1998;177:557–564.
   PubMed Web of Science ®Google Scholar
• Antiretroviral Pregnancy Registry. Wilmington, NC: PharmaResearch Corporation; January 1989 - July 1997.
   Google Scholar
• CuInane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281:151–157.
   PubMed Web of Science ®Google Scholar
• Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:463–467.
   PubMedGoogle Scholar
• Bardeguez A, Mofenson LM, Fowler M, et al. Lack of clinical or immunologic disease progression with transient use of zidovudine (ZDV) to reduce perinatal HIV transmis-sion in PACTG 076. 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12233.
   Google Scholar
• Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and hyperimmune HIV immunoglobulin for re-ducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis. 1999;179:567–575.
   PubMed Web of Science ®Google Scholar
• Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial. Lancet. 1999;353:773–780.
   PubMed Web of Science ®Google Scholar
• Lallemont M, Jourdain G, Kim S, et al. Perinatal HIV Pre-vention Trial (PHT), Thailand: DSMB recommends termi-nation of short-short arm after first interim analysis. Sec-ond Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants; September 1–6, 1999; Montreal, Canada. Abstract 016.
   Google Scholar
• Saba J on behalf of the PETRA Trial Study Team. Interim analysis of early efficacy of three short ZDV/3TC combina-tion regimens to prevent mother-to-child transmission of HIV-1: The PETRA trial. Sixth Conference on Retroviruses and Opportunistic Infections; January 1999; Chicago, IL. Abstract S–7.
   Google Scholar
• Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802.
   PubMed Web of Science ®Google Scholar
• Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal trans-mission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409–1414.
   PubMed Web of Science ®Google Scholar
• Wade N, Birkhead GS, French PT. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med. 1999;340:1042–1043.
   PubMed Web of Science ®Google Scholar
• CDC. Case-control study of HIV seroconversion in health-care workers after precutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988 to August 1994. MMWR. 1995;44:929–933.
   PubMedGoogle Scholar
• Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997;3:549–552.
   PubMed Web of Science ®Google Scholar
• Dickover RE, Garratty EM, Norman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. JAMA. 1996;275:599–605.
   PubMed Web of Science ®Google Scholar
• Mayaux M-J, Dussaix E, lsopet J, et al. Maternal virus load during pregnancy and the mother-to-child transmission of human immunodeficiency virus type 1: The French Perina-tal Cohort Studies. J Infect Dis. 1997;175:172–175.
   PubMed Web of Science ®Google Scholar
• Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. J Infect Dis. 1997;175:707–711.
   PubMed Web of Science ®Google Scholar
• Shapiro DE, Sperling RS, Coombs RW. Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. Lancet. 1999;354:156.
   PubMed Web of Science ®Google Scholar
• Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med. 1999;341:385–393.
   PubMed Web of Science ®Google Scholar
• Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341:394–402.
   PubMed Web of Science ®Google Scholar
• The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one. AIDS. 1999;13:1377–1385.
   PubMed Web of Science ®Google Scholar
• Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child transmission, Bangkok, Thailand. AIDS. 1999;13:407–414.
   PubMed Web of Science ®Google Scholar
• Shaffer N, Roongpisuthipong A, Siriwasin W, et al. Mater-nal virus load and perinatal human immunodeficiency vi-rus subtype E transmission, Thailand. J Infect Dis. 1999;179:590–599.
   PubMed Web of Science ®Google Scholar
• Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis. 1999;179:871–882.
   PubMed Web of Science ®Google Scholar
• Iverson AKN, Larsen AR, Jensen T, et al. Distinct determi-nants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions. J Infect Dis. 1998;177:1214–1220.
   PubMed Web of Science ®Google Scholar
• Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ. Analysis of HIV-1 in cervicovaginal secretions and blood of pregnant and non-pregnant women. J Hum Virol. 1999;2:154–166.
   PubMedGoogle Scholar
• Rasheed S, Li Z, Xu D, Kovacs, A. Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet GynecoL 1996;175:122–129.
   PubMed Web of Science ®Google Scholar
• Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Infect Dis. 2000;181:99–106.
   PubMed Web of Science ®Google Scholar
• Melvin AJ, Burchett SK, Watts DH, et al. Effect of preg-nancy and zidovudine therapy on viral load in HIV-1-in-fected women. J Acquir Immune Defic Syndr Hum RetroyiroL 1997;14:232–236.
   PubMedGoogle Scholar
• The Women and Infants Transmission Study. Trends in mother-to-infant transmission of HIV in the WITS cohort: Impact of 076 and HAART therapy. Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants; September 1–6, 1999; Montreal, Canada. Abstract 212.
   Google Scholar
• McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet GynecoL 1999;94:641–646.
   PubMed Web of Science ®Google Scholar
• Burns DN, Landesman S, Muenz LR, et al. Cigarette smok-ing, premature rupture of membranes and vertical trans-mission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr Hum RetroyiroL 1994;7:718–726.
   Google Scholar
• Turner BJ, Hauck WW, Fanning R, Markson LE. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Human RetroyiroL 1997;14:327–337.
   PubMedGoogle Scholar
• Rodriguez EM, Mofenson LM, Chang B-H, et al. Associa-tion of maternal drug use during pregnancy with maternal HIV culture postivity and perinatal HIV transmission. AIDS. 1996;10:273–282.
   PubMed Web of Science ®Google Scholar
• Bulterys M, Landesman S, Burns DN, Rubinstein A, Goedert J. Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. J Acquir Immune Defic Syndr Human RetroyiroL 1997;15:76–82.
   PubMedGoogle Scholar
• Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavior during pregnancy and perinatal transmission of HIV-1. AIDS. 1996;10:1249–1256.
   PubMed Web of Science ®Google Scholar
• CDC. Recommendations for assisting in the prevention of perinatal transmission of human T-Iymphotropic virus type III/Iymphadenopathy-associated virus and acquired immu-nodeficiency syndrome. MMWR. 1985;34:721–726.
   PubMedGoogle Scholar
• Rodman JH, Robbins BL, Flynn PM, Fridland A. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. J Infect Dis. 1996;174:490–499.
   PubMed Web of Science ®Google Scholar
• Barry MG, Khoo SH, Beal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated me-tabolites. AIDS. 1996;10:1361–1367.
   PubMed Web of Science ®Google Scholar
• Gambertoglio JG, Peter K. Zidovudine phosphorylation af-ter short term and long term therapy with zidovudine in patients infected with HIV. Clin Pharmacol Ther. 1996;60:168–176.
   PubMed Web of Science ®Google Scholar
• Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: A randomized, double-blind placebo controlled study. AIDS. 1994;8:313–321.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Gringeri A, Savidge G, et al. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. Brit J HaematoL 1994;86:174–179.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in per-sons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med. 1993; 329:297–303.
   PubMed Web of Science ®Google Scholar
• Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993;122:1137–1144.
   Web of Science ®Google Scholar
• Mirochnick M, Capparelli E, Dankner W, et al. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrobial Agents Chemother. 1998;42:808–812.
   PubMed Web of Science ®Google Scholar
• The Delta Coordinating Committee. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283–291.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081–1090.
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Winslow DL, Collins G et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millime-ter. N Engl J Med. 1996;335:1099–1106.
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR. Clinical significance of drug resistance in HIV-1 infection. AIDS. 1996;10\(suppl 5):527–531.
   PubMed Web of Science ®Google Scholar
• Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients af-ter long-term zidovudine treatment. J Infect Dis. 1995;171:1172–1179.
   PubMed Web of Science ®Google Scholar
• Miotti PG, Taha TET, Kumwenda NI, et al. HIV transmis-sion through breastfeeding-a study in Malawi. JAMA. 1999;282:744–749.
   PubMed Web of Science ®Google Scholar
• Koup RA, Brewster F, Grob P, Sullivan JL. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. AIDS. 1993;7:1181–1184.
   PubMed Web of Science ®Google Scholar
• Musoke P, Gyay L, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479–486.
   PubMed Web of Science ®Google Scholar
• Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ. Kinetic analysis of intravirion reverse tran-scription in the blood plasma of human immunodeficiency virus type 1-infected individuals: Direct assessment of resistance to reverse transcriptase inhibitors in vivo. J ViroL 1996;70:628–634.
   PubMed Web of Science ®Google Scholar
• Frenkel LM, Wagner LE, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and verti-cal transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995;20:1321–1326.
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977–1983.
   PubMed Web of Science ®Google Scholar
• Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary infection. JAMA. 1999;282:1142–1149.
   PubMed Web of Science ®Google Scholar
• Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135–1141.
   PubMed Web of Science ®Google Scholar
• Pomerantz RJ. Primary HIV-1 resistance: A new phase in the epidemic? JAMA. 1999;282:1177-1179.
   Google Scholar
• Palumbo P, Dobbs T, Holland B, et al. Antiretroviral (ARV) resistance mutations among pregnant, HIV-infected women: frequency and clinical correlates. Second Confer-ence on Global Strategies for the Prevention of HIV Trans-mission from Mothers to Infants; September 1–6, 1999; Montreal, Canada. Abstract 256.
   Google Scholar
• KuIly C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. J Infect 0is. 1999;179:705–708.
   PubMed Web of Science ®Google Scholar
• Colgrove RC, Pitt J, Chung PH, Welles SL, Japour AJ. Selective vertical transmission of HIV-1 antiretroviral resis-tance mutations. AIDS. 1998;12: 2281–2288.
   PubMed Web of Science ®Google Scholar
• Van Rompay KKA, Otsyula MG, Marthas ML, Miller C, McChesney MB, Pedersen NC. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 1995;39:125–131.
   PubMed Web of Science ®Google Scholar
• Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infec-tion in macaques by (R)-9-(2- phosphonyl-methoxypropyI)-adenine. Science. 1995;270:1197–1199.
   PubMed Web of Science ®Google Scholar
• Bottiger D, Johansson N-G, Samuelsson B, et al. Preven-tion of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS. 1997;11:157–162.
   PubMed Web of Science ®Google Scholar
• Mathes LE, Polas PJ, Hayes KA, et al. Pre- and post-exposure chemoprophylaxis: Evidence that 3'-azido-3'dideoxythymidine (AZT) inhibits feline leukemia virus dis-eases by a drug-induced vaccine effect. Antimicrob Agents Chemother. 199236: 2715–2721.
   Google Scholar
• Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS. 1995;9:F7–F11.
   PubMed Web of Science ®Google Scholar
• The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodefi-ciency virus type 1 - A meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340:977–987.
   PubMed Web of Science ®Google Scholar
• The European Mode of Delivery Collaboration. Elective ce-sarean-section versus vaginal delivery in prevention of ver-tical HIV-1 transmission: A randomized clinical trial. Lancet. 1999;353:1035–1039.
   PubMed Web of Science ®Google Scholar
• Amer/can College of Obstetricians and Gynecologists Com-mittee Opinion. Scheduled cesarean delivery and the pre-vention of vertical transmission of HIV infection. Number 234; May 2000.
   Google Scholar
• Burns DN, Landesman S, Wright DJ, et al. Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human im-munodeficiency virus type 1. J Infect Dis. 1997; 175:1206–1210.
   PubMed Web of Science ®Google Scholar
• Coll O, Hernandez M, Boucher CAB, et al. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J Acquir Immune Defic Syndr Hum RetroviroL 1997;14:26–30.
   PubMedGoogle Scholar
• Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis. 1999;179:319–328.
   PubMed Web of Science ®Google Scholar
• Samelson R, Shapiro D, Tuomala, et al. HIV vertical trans-mission rates according to antiretroviral therapy and viral load during pregnancy among 347 mother-child pairs 1998–99 (PACTG 367). Poster presentation at the Society for Maternal Fetal Medicine annual meeting; January 2000; Miami Beach, FL. Abstract 276.
   Google Scholar
• Clarke SM, Mulcahy F, Healy CM, et al. The efficacy and tolerability of combination antiretroviral therapy in preg-nancy: Infant and maternal outcome. Int J STD AIDS. 2000;11:220–223.
   PubMed Web of Science ®Google Scholar
• Beckerman KP, Morris AB, Stek A. Mode of delivery and the risk of vertical transmission of HIV-1 (letter). N Engl J Med. 1999;341: 205.
   PubMed Web of Science ®Google Scholar
• The Women and Infants Transmission Study Investigators. Trends in mother-to-infant transmission of HIV in the WITS cohort: Impact of 076 and HAART therapy. Presented at the XIII International AIDS Conference; July 2000; Durban, South Africa. Abstract LBOr4.
   Google Scholar
• Helfgott A, Eriksen N, Lewis S, et al. Highly active antiretroviral therapy for the prevention of perinatal HIV. Poster presentation at the Society for Maternal Fetal Medi-cine annual meeting; January 2000; Miami Beach, FL. Ab-stract 289.
   Google Scholar
• Nielsen TF, Hakegaard KH. Postoperative cesarean section morbidity: A prospective study. Am J Obstet Gynecol. 1983;146:911–915.
   PubMed Web of Science ®Google Scholar
• Hebert PR, Reed G, Entman SS, Mitchell EF, Berg C, Griffin MR. Serious maternal morbidity after childbirth: Prolonged hospital stays and readmissions. Obstet Gynecol. 1999;94:942–947.
   PubMed Web of Science ®Google Scholar
• Roman J, Bakos O, Cnattingius S. Pregnancy outcomes by mode of delivery among term breech births: Swedish expe-rience 1987-1993. Obstet Gynecol. 1998;92:945–950.
   PubMed Web of Science ®Google Scholar
• Gregory KD, Henry OA, Ramicone E, Chan LS, Platt LD. Maternal and infant complications in high and normal weight infants by method of delivery. Obstet Gynecol. 1998;92:507–513.
   PubMed Web of Science ®Google Scholar
• Schiff E, Friedman SA, Mashiach S, Hart O, Barkai G, Sibai BM. Maternal and neonatal outcome of 846 term singleton breech deliveries: Seven-year experience at a single center. Am J Obstet Gynecol. 1996;175:18–23.
   PubMed Web of Science ®Google Scholar
• Van Ham MAPC, van Dongen PWJ, Mulder J. Maternal consequences of caesarean section. A retrospective study of intra-operative and postoperative maternal complica-tions of caesarean section during a 10-year period. Eur J Obstet Gynecol Repro Biol. 1997;74:1–6.
   PubMed Web of Science ®Google Scholar
• McMahon MJ, Luther ER, Bowes WA Jr, Olshan AF. Com-parison of a trial of labor with an elective second cesarean section. N Engl J Med. 1996;335:689–695.
   PubMed Web of Science ®Google Scholar
• Watts DH, Lambert JS, Stiehm ER, et al. for the Pediatric AIDS Clinical Trials Group 185 Team. Complications ac-cording to mode of delivery among HIV-infected women with CD4 lymphocyte counts of 500 or less. Amer J Obstet Gynecol. 2000;173:100–107.
   Google Scholar
• Read J, Kpamegan E, Tuomala R, et al. Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study (WITS). In: Abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract 683.
   Google Scholar
• Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after cesarean section in 156 HIV-posi-tive women. AIDS. 1996;9:913–917.
   Web of Science ®Google Scholar
• Grubert TA, Reindell D, Kastner R, et al. Complications after caesarean section in H IV-1-infected women not tak-ing antiretroviral treatment. Lancet. 1999;354:1612–1613.
   PubMed Web of Science ®Google Scholar
• Maiques-Montesinos V, Cervera-Sanchez J, Beliver-Pradas J, et al. Post-cesarean section morbidity in HIV-positive women. Acta Obstet Gynecol Scand. 1999;78:789–792.
   PubMed Web of Science ®Google Scholar
• Vimercati A, Greco P, Loverro G, et al. Maternal complica-tions after caesarean section in HIV infected women. Eur J Obstet Gynecol Reprod Biol. 2000;90:73–76.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists Educational Bulletin. Assessment of fetal lung maturity. Number 230; November 1996.
   Google Scholar
• Parilla BV, Dooley SL, Jansen RD, Socol ML. latrogenic respiratory distress syndrome following elective repeat cesarean delivery. Obstet Gynecol. 1993;81:392–395.
   PubMed Web of Science ®Google Scholar
• Madar J, Richmond S, Hey E. Surfactant-deficient respira-tory distress after elective delivery at "term." Acta Paediatr. 1999;88: 1244–1248.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists Educational Bulletin. Antimicrobial therapy for obstetric patients. Number 245; March 1998.
   Google Scholar
• Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical trans-mission of human immunodeficiency virus. Am J Obstet Gynecol. 1995;173:585–589.
   PubMed Web of Science ®Google Scholar
• Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med. 1996;334:1617–1623.
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immu-nodeficiency virus type 1: The French Perinatal Cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol. 1996;175:661–667.
   PubMed Web of Science ®Google Scholar
• Shapiro DE, Sperling RS, Mandelbrot L, et al. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Pediatric AIDS Clinical Trials Group protocol 076 Study Group. Obstet Gynecol. 1999;94:897–908.
   PubMed Web of Science ®Google Scholar
• Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1: Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA. 1994;271:1925–1930.
   PubMed Web of Science ®Google Scholar
• Kind C, Rudin C, Siegrisi CA, et al. Prevention of vertical HIV transmission: Additive protective effect of elective cesarean section and zidovudine prophylaxis. AIDS. 1998;12:205–210.
   PubMed Web of Science ®Google Scholar
• Miotti PG, Liomba G, Dallabetta GA, Hoover DR, Chiphangwi JD, Saah AJ. T-lymphocyte subsets during and after pregnancy: Analysis in human immunodefi-ciency virus type 1-infected and uninfected Malawian mothers. J Infect Dis. 1992;165:1116–1119.
   PubMed Web of Science ®Google Scholar
• Tuomala RE, Kalish LA, Zorilla C, et al. Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-in-fected women. Obstet Gynecol. 1997;89:967–974.
   PubMed Web of Science ®Google Scholar
• CDC. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR. 1995;44:1–11.
   Google Scholar
• American Academy of Pediatrics, Committee on Pediatric AIDS. Evaluation and medical management of the HIV-exposed infant. Pediatrics. 1997;99: 909–917.
   PubMed Web of Science ®Google Scholar
• Kovacs A, Xu J, Rasheed S, et al. Comparison of a rapid nonisotopic polymerase chain reaction assay with four commonly used methods for the early diagnosis of human immunodeficiency virus type 1 infection in neonates and children. Pediatr Infect Dis J. 1995;14:948–954.
   PubMed Web of Science ®Google Scholar